BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS. (PRIMIDIEP)
Primary Purpose
Breast Cancer
Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Mechanical ischemic preconditioning of diep-type flap
Sponsored by
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring Breast reconstruction, Ischaemic preconditioning, DIEP flap
Eligibility Criteria
Inclusion Criteria:
- female with age ≥ 18
- Secondary unilateral breast reconstruction using DIEP
- Signed consent form
- Beneficiary of a social security scheme
Exclusion Criteria:
- Smoking: active or quit since < 2 months, contraindication for flap surgery
- Pregnancy: contraindication for surgery
- Immediate breast reconstruction, at the same time as the mastectomy (increases cutaneous complications and different surgical technique)
- Bilateral breast reconstruction (increases operation time and post operation complications)
- Patient under curatorship or guardianship
- Patient deprived of their liberty, and patient undergoing psychiatric care
- Risk factor for DIEP complication such as: previous surgical procedures performed on the abdomen, carcinological treatments and severe comorbidities of the patient.
- Risk factors for complications of mechanical preconditioning. Soft tissue inflammation or osteomyelitis, peripheral arterial occlusive disease, vasculitis,
- Participation in another interventional study
- Any contraindication to general anesthesia
Sites / Locations
- Service Plastique, Reconstruction, Esthétique, Hôpital TENON- APHP
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Group intervention
Arm Description
PIM - DIEP
Outcomes
Primary Outcome Measures
Number of successes of the technique defined by the absence of pathological postoperative fat necrosis
Number of successes of the technique defined by the absence of pathological postoperative fat necrosis to evaluate the efficacy of ischaemic preconditioning on the tolerance of the adipose tissue to the ischemia-reperfusion of DIEP flaps
Secondary Outcome Measures
to evaluate the efficacy of ischaemic preconditioning on the tolerance of the skin (cutaneous necrosis, scar separation) to the ischemia-reperfusion of DIEP flaps
proportion of patients with skin necrosis
Presence of skin necrosis within 6 months postoperatively defined by (occurrence of one or more of the three subcited elements
Skin infection
Skin necrosis of the flap
Scar disunion
Proportion of overall reconstruction failures: postoperative flap loss at M6: flap removal for total necrosis
Rate of subclinical cystosteatonecrosis (detected by ultrasound at M6: presence of one or more nodules, measuring more than 5mm but having no clinical repercussions)
to evaluate the proportion of overall failure after DIEP type flaps.
Proportion of overall reconstruction failure (need to remove the flap for total necrosis)
to evaluate the proportion of subclinical cytosteatonecrosis
rate of subclinical cysteatonecrosis
Full Information
NCT ID
NCT05373069
First Posted
March 4, 2022
Last Updated
May 9, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
INSERM Bichat hospital
1. Study Identification
Unique Protocol Identification Number
NCT05373069
Brief Title
BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.
Acronym
PRIMIDIEP
Official Title
BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 2022 (Anticipated)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
INSERM Bichat hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Breast cancer is the most common cancer amongst women in terms of frequency, with more than 50 000 newly diagnosed cases per year in France. The average 5-year survival rate for women with breast cancer is around 85%. Surgical treatment by total mastectomy concerns around 30% of cases. For patients who have been treated for breast cancer by total mastectomy, secondary breast reconstructions are often carried out via excess abdominal fat flaps of DIEP type.
Postoperative partial fat necrosis is a common complication of breast reconstruction. This necrosis is qualified as pathological when it is palpable or when there are symptoms leading to pain, deformation, or leakage. Necrosis occurs in the first 6 months after surgery. Diagnosis is carried out by the detection of a nodule of fat necrosis measuring at least 5 mm on the ultrasound.
Partial flat necrosis results from ischemia reperfusion (IR) to the fat tissues during reconstruction. IR leads to inflammatory lesions, edema, capillary occlusion that can lead to tissue necrosis. The deleterious impact of IR has been shown on the organs (liver, kidney) on muscular, cutaneous and adipose tissues in humans and animals.
Ischaemic preconditioning is a procedure used in organ transplant surgery, allowing a better tolerance of the graft for ischemia reperfusion, without further complications. It is used in usual practice for kidney or liver transplants; short cycles of ischemia reperfusion are carried out on the organ pedicle before harvesting using cold ischemia (out of the donor's body) pre-transplant.
Ischaemic preconditioning before reconstruction has been studied in animal models but not in human reconstruction surgery, although it seems to be beneficial. For patients undergoing total mastectomy after being diagnosed with breast cancer, we hypothesize that ischaemic preconditioning, usually used for organ transplants, could decrease adipose tissue lesions caused by ischemia reperfusion after breast reconstruction with DIEP (deep inferior epigastric perforator) flaps.
Detailed Description
This is a phase 2 monocentric study, following the 2 step Simon Minimax design.
We will be carrying out cycles of ischemic preconditioning for 40 minutes, simulating 2 cycles of ischemia-reperfusion (per 10min) prior to flap harvesting and cold ischemia before revascularization.
The pre operation visit will occur between M3 and M1 before the scheduled operation date. The visit will be carried out by the surgeon who will inform the patient of the study.
The inclusion visit (D0) will be carried out by the investigator the day before surgery (collection of signed consent form). The surgery will be carried out as usual: breast reconstruction with DIEP type flap. Modification of the intervention for the study: preconditioning of the flap (for patients) and 3 biopsies.
During post-operative hospitalization, usual visits will be carried out twice a day (not specifically for the study) by an doctor (to check for vascular damage, hematoma, infection, cutaneous necrosis, leakage and scar separation).
After postoperative discharge, 4 follow up visits are planned which correspond to 3 postoperative consultations at the hospital (to check for vascular damage, hematoma, infection, cutaneous necrosis, leakage and scar separation) at D21 (+/- 2 days), M1 (+/- 2 days), M3 (+/- 15 days, same assessment plus search for palpable, painful or deforming nodules) and M6 (+/- 15 days, last visit) plus a mammary ultrasound (this is the only supplementary assessment carried out for the study, Tenon hospital).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast reconstruction, Ischaemic preconditioning, DIEP flap
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
35 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group intervention
Arm Type
Experimental
Arm Description
PIM - DIEP
Intervention Type
Procedure
Intervention Name(s)
Mechanical ischemic preconditioning of diep-type flap
Intervention Description
Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)
10 min of clamping with single-use microvascular forceps
10 min declamping
10 min of tightening with pliers
10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization.
Primary Outcome Measure Information:
Title
Number of successes of the technique defined by the absence of pathological postoperative fat necrosis
Description
Number of successes of the technique defined by the absence of pathological postoperative fat necrosis to evaluate the efficacy of ischaemic preconditioning on the tolerance of the adipose tissue to the ischemia-reperfusion of DIEP flaps
Time Frame
6 months post operation
Secondary Outcome Measure Information:
Title
to evaluate the efficacy of ischaemic preconditioning on the tolerance of the skin (cutaneous necrosis, scar separation) to the ischemia-reperfusion of DIEP flaps
Description
proportion of patients with skin necrosis
Time Frame
6 months post operation
Title
Presence of skin necrosis within 6 months postoperatively defined by (occurrence of one or more of the three subcited elements
Description
Skin infection
Skin necrosis of the flap
Scar disunion
Time Frame
6 months post operation
Title
Proportion of overall reconstruction failures: postoperative flap loss at M6: flap removal for total necrosis
Time Frame
6 months post operation
Title
Rate of subclinical cystosteatonecrosis (detected by ultrasound at M6: presence of one or more nodules, measuring more than 5mm but having no clinical repercussions)
Time Frame
6 months post operation
Title
to evaluate the proportion of overall failure after DIEP type flaps.
Description
Proportion of overall reconstruction failure (need to remove the flap for total necrosis)
Time Frame
6 months post operation
Title
to evaluate the proportion of subclinical cytosteatonecrosis
Description
rate of subclinical cysteatonecrosis
Time Frame
6 months post operation
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
female with age ≥ 18
Secondary unilateral breast reconstruction using DIEP
Signed consent form
Beneficiary of a social security scheme
Exclusion Criteria:
Smoking: active or quit since < 2 months, contraindication for flap surgery
Pregnancy: contraindication for surgery
Immediate breast reconstruction, at the same time as the mastectomy (increases cutaneous complications and different surgical technique)
Bilateral breast reconstruction (increases operation time and post operation complications)
Patient under curatorship or guardianship
Patient deprived of their liberty, and patient undergoing psychiatric care
Risk factor for DIEP complication such as: previous surgical procedures performed on the abdomen, carcinological treatments and severe comorbidities of the patient.
Risk factors for complications of mechanical preconditioning. Soft tissue inflammation or osteomyelitis, peripheral arterial occlusive disease, vasculitis,
Participation in another interventional study
Any contraindication to general anesthesia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sarra CRISTOFARI, MD, PhD
Phone
+33 6 30 33 39 56
Email
sarra.cristofari@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Michael ATLAN, PU-PH
Phone
0156017000
Email
drmichaelatlan@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarra CRISTOFARI, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service Plastique, Reconstruction, Esthétique, Hôpital TENON- APHP
City
Paris
ZIP/Postal Code
75020
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara CRISTOFARI, MD, PhD
Phone
+33 6 30 33 39 56
Email
sarra.cristofari@gmail.com
First Name & Middle Initial & Last Name & Degree
Michael ATLAN, PU-PH
Phone
0156017000
Email
drmichaelatlan@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.
We'll reach out to this number within 24 hrs